Yiling Pharmaceuticals: Registration application for clinical trials of new traditional Chinese medicine "Qilong Dingchuan tablets" approved.

Yiling Pharmaceutical announced that on March 26, 2026, the company received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The new Chinese medicine "Qilong Dingchuan Pills" is classified as a Class 1.1 new Chinese medicine, with indications for chronic obstructive pulmonary disease in the stable phase of heart-lung qi deficiency and phlegm stasis obstruction syndrome, in tablet form. The approval conclusion is: to approve the clinical trial of this product for chronic obstructive pulmonary disease in the stable phase of heart-lung qi deficiency and phlegm stasis obstruction syndrome.